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Italy has been the first nation in the European Union affected 
by the Coronavirus epidemic and is the first in the world for 
number of reported deaths. As of March 31, 101,739 posi-
tive cases were reported (42,161 of them in the Lombardy 
region), as well as 11,591 deaths. With regard to children, 
we have 1226 positive cases between the ages of 0 and 
18 years, that is, 1.3% of total infections. Based on avail-
able evidence, children do not appear to be at higher risk for 
COVID-19 than adults; indeed, they appear to experience 
a milder form of the infection. The reasons for the relative 
resistance of children are still unknown, and may be related 
to a different immune response, to healthier respiratory tracts 
secondary to shorter air pollution exposure and absence of 
cigarette smoke, and to a lack of comorbidities [1].
In our Pediatric Rheumatology Unit, we treat more than 
2000 young patients with chronic rheumatological inflam-
matory disorders, and almost 500 of them are on biologic 
therapies. Parents are very worried about the possibility of 
their children contracting COVID-19 infection due to immu-
nosuppression. We receive hundreds of telephone calls, and 
feel that a uniform response by healthcare providers (and 
pediatric rheumatologists in particular) is necessary in order 
to avoid wrong messages and possibly a negative outcome on 
patients’ health due to incorrect treatment recommendations.
In our center, we recommend simple measures to prevent 
contact with infected subjects and spread of the virus. In 
particular, we underline the importance of regular cleaning 
of hands with soap or alcohol-based sanitizers, of avoiding 
contact with people who manifest respiratory symptoms, of 
coughing or sneezing not on palms but into the elbow, and 
of not touching their own face as much as possible. We do 
not recommend emergency department visits unless strictly 
necessary, but if new symptoms arise a national telephone 
number is available, and we have also instituted in our hos-
pital an on-call specific number to answer clinical questions 
or doubts about behaviors to adopt. Outpatient visits and 
elective hospitalizations are limited to those considered non-
deferrable. Currently, recommendations of rheumatologic 
societies both in Italy and Europe suggest continuation of all 
immunosuppressant therapies as usual. In fact, withdrawal 
of medications may cause a flare of inflammatory disease, 
which can lead to higher infection risk [2]. In case of fever 
or respiratory symptoms, patients should consult the treating 
physician. Following these rules, up to the time of writing 
(31 March 2020), we have not yet heard of a COVID-19 case 
in our patient cohort, and disease relapses have been mild 
and no different from before the epidemic spread.
In recent days, scientific societies such as the European 
League Against Rheumatism (EULAR) and the Italian Soci-
ety of Rheumatology (SIR) have created databases to moni-
tor and report outcomes of COVID-19 in patients suffering 
from autoimmune or autoinflammatory diseases [3, 4]. The 
aim is to understand how epidemiological factors such as 
age, comorbidities, and different immunosuppressant treat-
ments can influence the course and outcomes of the COVID-
19 infection. We believe that, in this complicated moment 
for our healthcare system, we can contribute to increasing 
knowledge about a poorly understood pathogen and may 
help pediatric rheumatologists to make better informed 
therapeutic decisions.
Unfortunately, we still know too little about the role of 
immunosuppressant agents in relation to COVID-19 infec-
tion. A stronger immune response, typical of the adult 
patient, could lead to a hyperactivation of the immune 
system and massive cytokine release associated with the 
development of acute respiratory distress syndrome (ARDS) 
occurring in the most aggressive patterns of COVID-19 
infection. In this scenario, drugs commonly used for the 
treatment of autoimmune diseases have been introduced for 
the management of critical cases of COVID-19. The ideal 
treatment for cytokine storm syndrome (CSS) induced by 
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COVID-19 infection is still unknown, but the role of rheu-
matologist could be crucial. First of all we are used to man-
aging cytokine-targeting therapies and are familiar with 
their side effects. In addition, rheumatologists have a strong 
background in understanding the immune system and can 
assist and work together with other specialists to treat those 
patients who develop CSS.
Currently, in Italy, six studies have been approved by the 
Italian Medicines Agency (AIFA): two of these involve the 
investigative antiviral drug remdesivir. The remaining tri-
als involve drugs used in pediatric rheumatology; two are 
focused on tocilizumab (an anti-IL-6R monoclonal antibody 
approved for juvenile idiopathic arthritis [JIA]), one on sari-
lumab (which also targets IL-6R and is in development for 
JIA) and another investigating intravenous administrations 
of emapalumab (anti-IFNγ) in combination with anakinra 
(an IL-1 receptor antagonist, approved for cryopyrin-asso-
ciated periodic syndromes and JIA). Moreover, a proposal 
for another open-label, phase II study to evaluate the efficacy 
and safety of colchicine treatment for Covid-19 infection is 
currently under evaluation by AIFA.
Another drug that is being investigated widely is hydroxy-
chloroquine (HCQ), an immunomodulatory agent commonly 
used in autoimmune diseases such as rheumatoid arthritis 
and systemic lupus erythematosus. However, its effective-
ness in treating COVID-19 pneumonia is still under evalu-
ation. There are controversial opinions about its efficacy in 
treating or preventing COVID-19 infection and until results 
from large clinical trials are available, the European Medi-
cines Agency (EMA) recommends its use only in the context 
of clinical trials, also to avoid consuming drug stocks. In 
fact, stockpiling of HCQ by otherwise healthy individuals is 
endangering rheumatology patients, who can no longer get 
hold of their regular prescription as there is little available. 
In some countries, prescribing of this medicine has been 
restricted to reduce the risk of shortages. Currently, there is 
only one registered completed Chinese study on HCQ, which 
evaluated the efficacy and safety of HCQ in this context, 
and the trial failed to demonstrate statistical superiority over 
placebo [5]. Other trials on HCQ are ongoing, both for treat-
ment of patients with proven COVID-19 infection as well 
as for its prevention; there is an urgent need to understand 
whether immunosuppressants could be a valid treatment 
option, and what type of patient will benefit.
With regard to pediatric populations, treatment indica-
tions for COVID-19 are not yet well defined. Based on a 
Chinese consensus, management is based on respiratory 
support and on the use of corticosteroids and intravenous 
immunoglobulins in selected cases [6]. What we know about 
pediatric immunosuppressed patients is derived from the 
experience of The Hospital Papa Giovanni XXIII in Ber-
gamo, a large pediatric hepatology and liver transplantation 
center. Out of about 200 transplant recipients, including ten 
inpatients and 100 with autoimmune liver disease, none have 
developed clinical pulmonary disease, despite three having 
tested positive for SARS-CoV-2 [7]; therefore, data suggest 
that immunosuppressed patients may not be at increased risk 
of severe infection compared with the general population. 
In addition, very recent Italian data show that adult patients 
with chronic arthritis and treated with biological DMARDs 
or traditional DMARDs do not seem to be at increased risk 
of respiratory or life-threatening complications from SARS-
CoV-2 compared with the general population [8].
Until results from clinical trials of antiviral and immu-
nomodulatory drugs are available, we will obviously con-
tinue to follow daily national recommendations and keep 
emphasizing that simple hygiene measures and social isola-
tion when prescribed by national authorities are the best, and 
for the time being, the only way to avoid epidemic spread. 
Protecting our young patients, as well as ourselves, is our 
mission now.
Compliance with Ethical Standards 
Conflict of interest The authors declare that they have no conflict of 
interest.
Funding No sources of funding were used to support the writing of 
this article. This article does not contain any studies with human par-
ticipants performed by any of the authors.
References
 1. Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children 
less susceptible to COVID-19? J Microbiol Immunol Infect. 2020. 
https ://doi.org/10.1016/j.jmii.2020.02.011.
 2. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, 
Caporali R. COVID-19 infection and rheumatoid arthritis: Fara-
way, so close! Autoimmun Rev. 2020. https ://doi.org/10.1016/j.
autre v.2020.10252 3.
 3. EULAR COVID-19 Rheumatological database. 2020. https ://
www.redca p.rss.mhs.man.ac.uk/surve ys/?s=NEXNJ FWX38 .
 4. SIR COVID-19 database. 2020. https ://www.reuma tolog ia.it/
cmsx.asp?IDPg=1092.
 5. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of 
hydroxychloroquine in treatment of patients with common corona-
virus disease-19 (COVID-19). J Zhejiang Univ (Medical Science). 
2020. https ://doi.org/10.3785/j.issn.1008-9292.2020.03.03.
 6. Shen K, Yang Y, Wang T, Zhao D, Jiang Y, et al. Diagnosis, 
treatment, and prevention of 2019 novel coronavirus infection in 
children: experts’ consensus statement. World J Pediatr. 2020. 
https ://doi.org/10.1007/s1251 9-020-00343 -7.
 7. D’Antiga L. Coronaviruses and immunosuppressed patients. The 
facts during the third epidemic. Liver Transpl. 2020. https ://doi.
org/10.1002/lt.25756 .
 8. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Mon-
tecucco C. Clinical course of COVID-19 in a series of patients 
with chronic arthritis treated with immunosuppressive targeted 
therapies. Ann Rheum Dis. 2020. https ://doi.org/10.1136/annrh 
eumdi s-2020-21742 4.
